[Adoptive immunotherapy in patients with malignant glioma].

We report preliminary results of adoptive immunotherapy in 12 patients with malignant glioma. The patients received both 1.8 to 20 X 10(8) autologous lymphokine activated killer (LAK) cells, and 8 to 16 X 10(4) units of interleukin-2. Objective regression of the tumor was observed in 8 patients. In 4 cases, the size of the tumor was remarkably reduced. No severe side effects were observed. Furthermore, LAK cells and their precursor cells were serologically studied.